45.24
+0.19(+0.42%)
Currency In CNY
Address
Building 2 Room 105, No. 230 Cailun RoadChina (Shanghai) Pilot Free Trade Zone Shanghai, 201210China
Shanghai, 201210
China
Phone
86 21 5833 2260
Website
Sector
Healthcare
Industry
Biotechnology
Employees
1416
First IPO Date
January 18, 2022
| Name | Title | Pay | Year Born |
| Dr. Datao Liu | Chairman, Chief Executive Officer & GM | 0 | 1972 |
| Dr. Xin Du | Chief Scientific Officer & President of Maiwei (US) | 0 | 1972 |
| Ms. Xi Chen | Deputy General Manager | 0 | 1980 |
| Mr. Huiguo Hu | Deputy GM, Secretary of the Board of Directors & Director | 0 | 1977 |
| Mr. Weiyi Dong | Deputy General Manager | 0 | 1957 |
| Dr. Yinhan Guo | Chief Research & Development Officer | 0 | 1971 |
| Mr. Han Li | Deputy General Manager | 0 | 1971 |
| Mr. Jinchao Zhang | Deputy General Manager | 0 | 1972 |
| Mr. Hua Ni | Deputy General Manager | 0 | 1970 |
| Mr. Shu Hai Wang | Deputy General Manager | 0 | 1974 |
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of biological products in China and internationally. The company offers its products for auto-immune, oncology, ophthalmologic, and infectious diseases, as well as metabolic disorders, etc. It offers JUNMAIKANG, an autoimmune Adalimumab injection. The company’s oncology products pipeline includes 9MW2821 and 6MW3211, which are in phase II of clinical trial; 9MW2921, 9MW3811, and 7MW3711, which are in phase I clinical trials; 9MW0321; and 8MW0511, which is in phase III clinical trial. It also develops autoimmune products, such as 9MW1911 and 9MW3811, which are in phase 1 clinical trial; metabolic products comprising MAILISHU and 9MW3011; ophthalmology candidates, including 9MW0813 and 9MW0211 that are in phase III clinical trial; and 9MW1411, an infectious product candidate. The company was founded in 2017 and is based in Shanghai, China.
